AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease
The company has "received Import and Market Permission in Form CT-20
(Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets
10 mg," AstraZeneca Pharma India said in a filing to BSE.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazenecas-dapagliflozin-tablets-get-dcgi-nod-for-patients-with-chronic-kidney-disease/articleshow/80722914.cms
(Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets
10 mg," AstraZeneca Pharma India said in a filing to BSE.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazenecas-dapagliflozin-tablets-get-dcgi-nod-for-patients-with-chronic-kidney-disease/articleshow/80722914.cms
Comments
Post a Comment